Drug Trial Radar · NCT05099159
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
400
Actual
Start
Oct 29, 2021
Primary completion
Jun 13, 2023
Study completion Oct 10, 2023
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks. During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks. During the study, the participants will: * record information about the participants' hot flashes in an electronic diary * answer questions about the participants' symptoms The doctors will: * check the participants' health * take blood samples * ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.
Conditions
- Vasomotor Symptoms Associated With Menopause
- Hot Flashes
Interventions
Elinzanetant (BAY3427080)Drug
120 mg elinzanetant orally once daily
PlaceboDrug
Matching placebo orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)Time frame: From baseline to Week 4
- Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)Time frame: From baseline to Week 12
- Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD)Time frame: From baseline to Week 4
- Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)Time frame: From baseline to Week 12
Locations
113 sites in 12 countries. Site status is shown where the registry gives one.
Accel Research Sites | Cahaba Medical Care - Birmingham, AL
Birmingham, Alabama
Women's Health Alliance of Mobile
Mobile, Alabama
Onyx Clinical Research - Peoria
Peoria, Arizona
Lynn Institute of the Ozarks
Little Rock, Arkansas
National Institute of Clinical Research - Garden Grove
Garden Grove, California
Clinical Trials Research - Lincoln
Lincoln, California
Torrance Clinical Research Institute, Inc. | Lomita, CA
Lomita, California
Women's Health Care Research | San Diego, CA
San Diego, California
Advanced Women's Health Institute | Denver Office, Greenwood Village, CO
Greenwood Village, Colorado
Physicians' Research Options, LLC | Red Rocks OBGYN
Lakewood, Colorado
Helix Biomedics, LLC
Boynton Beach, Florida
Clinical Research of West Florida | Clearwater, FL
Clearwater, Florida
Sweet Hope Research Specialty, Inc. - Miami Lakes
Hialeah, Florida
Ocean Blue Medical Research Center, Inc | Miami Springs, FL
Miami Springs, Florida
Suncoast Clinical Research Inc. | Pasco
New Port Richey, Florida
Sensible Healthcare, LLC
Ocoee, Florida
Clinical Research of West Florida | Tampa, FL
Tampa, Florida
Fellows Research Alliance, Inc | Savannah, GA
Savannah, Georgia
Family Care Research | Boise, ID
Boise, Idaho
Leavitt Clinical Research | Idaho Falls, ID
Idaho Falls, Idaho
University of Chicago | Laboratory of Dr. Al-Hendy
Chicago, Illinois
AMR - Chicago
Oak Brook, Illinois
Clinical Trials Management | Northshore Office
Covington, Louisiana
Tandem Clinical Research | Marrero, LA
Marrero, Louisiana
Ob and Gyn Physicians MidAtlantic - SKYCRNG
Oxon Hill, Maryland
Genesis Clinical Research and Consulting, LLC
Fall River, Massachusetts
Saginaw Valley Medical Research Group, LLC | Saginaw, MI
Saginaw, Michigan
Metro Jackson OBGYN | Jackson, MS
Jackson, Mississippi
R. Garn Mabey Jr. M.D. Gynecology
Las Vegas, Nevada
Capital Health | Capital Health OBGYN Lawrenceville
Lawrenceville, New Jersey
Columbia University Medical Center
New York, New York
Eastern Carolina Women's Center | New Bern, NC
New Bern, North Carolina
Unified Women's Clinical Research | Raleigh, NC
Raleigh, North Carolina
OHSU Hospital - OB-GYN - Women's Health Research Unit
Portland, Oregon
UPMC Magee-Women's Hospital - Gynecology
Pittsburgh, Pennsylvania
Tribe clinical Research LLC | Greenville, SC
Greenville, South Carolina
Medical Research Center of Memphis | Memphis, TN
Memphis, Tennessee
Research Memphis Associates, LLC | Memphis, TN
Memphis, Tennessee
Austin Regional Clinic | ARC Kelly Lane
Austin, Texas
DiscoveResearch, Inc.
Bryan, Texas
Showing 40 of 113 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.